The Key Laboratory of TCM Collateral Disease Theory Research, School of Traditional Chinese Medicine, Capital Medical University, Beijing, 100069, PR China.
Traditional Chinese Medicine (TCM) Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, PR China.
Biomaterials. 2024 Dec;311:122670. doi: 10.1016/j.biomaterials.2024.122670. Epub 2024 Jun 17.
After orthopedic surgeries, such as hip replacement, many patients are prone to developing deep vein thrombosis (DVT), which in severe cases can lead to fatal pulmonary embolism or major bleeding. Clinical intervention with high-dose anticoagulant therapy inevitably carries the risk of bleeding. Therefore, a targeted drug delivery system that adjusts local DVT lesions and potentially reduces drug dosage and toxic side effects important. In this study, we developed a targeted drug delivery platelet-derived nanoplatform (AMSNP@PM-rH/A) for DVT treatment that can simultaneously deliver a direct thrombin inhibitor (DTI) Recombinant Hirudin (rH), and the Factor Xa inhibitor Apixaban (A) by utilizing Aminated mesoporous silica nanoparticles (AMSNP). This formulation exhibits improved biocompatibility and blood half-life and can effectively eliminate deep vein thrombosis lesions and achieve therapeutic effects at half the dosage. Furthermore, we employed various visualization techniques to capture the targeted accumulation and release of a platelet membrane (PM) coating in deep vein thrombosis and explored its potential targeting mechanism.
骨科手术后，如髋关节置换术，许多患者容易发生深静脉血栓形成（DVT），在严重情况下可导致致命性肺栓塞或大出血。临床采用大剂量抗凝治疗不可避免地存在出血风险。因此，需要开发一种靶向药物输送系统，以调节局部 DVT 病变，并可能减少药物剂量和毒副作用。在这项研究中，我们开发了一种用于 DVT 治疗的靶向药物输送血小板衍生纳米平台（AMSNP@PM-rH/A），该平台可以同时输送直接凝血酶抑制剂（DTI）重组水蛭素（rH）和因子 Xa 抑制剂阿哌沙班（A），利用氨化介孔硅纳米颗粒（AMSNP）。该制剂具有改善的生物相容性和血液半衰期，可以有效消除深静脉血栓形成病变，并在半剂量下实现治疗效果。此外，我们采用了各种可视化技术来捕捉血小板膜（PM）涂层在深静脉血栓形成中的靶向积累和释放，并探索了其潜在的靶向机制。
